AP2002002586A0 - Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. - Google Patents
Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.Info
- Publication number
- AP2002002586A0 AP2002002586A0 APAP/P/2002/002586A AP2002002586A AP2002002586A0 AP 2002002586 A0 AP2002002586 A0 AP 2002002586A0 AP 2002002586 A AP2002002586 A AP 2002002586A AP 2002002586 A0 AP2002002586 A0 AP 2002002586A0
- Authority
- AP
- ARIPO
- Prior art keywords
- substituted lower
- compounds
- nr9r10
- pyrido
- pyrimidine
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- QRRCMVPZJCHBLQ-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-2,7-diamine Chemical compound C1=NC(N)=NC2=NC(N)=CC=C21 QRRCMVPZJCHBLQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17826100P | 2000-01-25 | 2000-01-25 | |
| PCT/IB2001/000069 WO2001055147A1 (en) | 2000-01-25 | 2001-01-23 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2002002586A0 true AP2002002586A0 (en) | 2002-09-30 |
Family
ID=22651853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2002/002586A AP2002002586A0 (en) | 2000-01-25 | 2001-01-23 | Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1254137A1 (cs) |
| JP (1) | JP4047010B2 (cs) |
| KR (1) | KR20020065939A (cs) |
| CN (1) | CN1395578A (cs) |
| AP (1) | AP2002002586A0 (cs) |
| AR (1) | AR030044A1 (cs) |
| AU (1) | AU2542501A (cs) |
| BG (1) | BG106850A (cs) |
| BR (1) | BR0107751A (cs) |
| CA (1) | CA2397961C (cs) |
| CO (1) | CO5261549A1 (cs) |
| CR (1) | CR6706A (cs) |
| CZ (1) | CZ20022475A3 (cs) |
| DZ (1) | DZ3266A1 (cs) |
| EA (1) | EA200200643A1 (cs) |
| EE (1) | EE200200405A (cs) |
| GT (1) | GT200100016A (cs) |
| HN (1) | HN2001000013A (cs) |
| HU (1) | HUP0204141A3 (cs) |
| IL (1) | IL150545A0 (cs) |
| IS (1) | IS6443A (cs) |
| MA (1) | MA26868A1 (cs) |
| MX (1) | MXPA02007221A (cs) |
| NO (1) | NO20023527L (cs) |
| OA (1) | OA12161A (cs) |
| PA (1) | PA8510701A1 (cs) |
| PE (1) | PE20011066A1 (cs) |
| PL (1) | PL356802A1 (cs) |
| SK (1) | SK10632002A3 (cs) |
| SV (1) | SV2002000294A (cs) |
| TN (1) | TNSN01014A1 (cs) |
| WO (1) | WO2001055147A1 (cs) |
| YU (1) | YU50402A (cs) |
| ZA (1) | ZA200205879B (cs) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| ES2372028T3 (es) | 2000-10-23 | 2012-01-13 | Glaxosmithkline Llc | Nuevo compuesto de 8h-pirido[2,3-d]pirimidin-7-ona trisustituida para el tratamiento de enfermedades mediadas por la csbp/p38 quinasa. |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| MXPA04010267A (es) | 2002-04-19 | 2005-02-03 | Smithkline Beecham Corp | Compuestos novedosos. |
| KR20050084027A (ko) * | 2002-11-28 | 2005-08-26 | 쉐링 악티엔게젤샤프트 | Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도 |
| US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| CA2579406A1 (en) * | 2004-09-21 | 2006-03-30 | F.Hoffmann-La Roche Ag | 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors |
| JP2008535822A (ja) | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| PE20100741A1 (es) | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
| UY29440A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| EP1865959A2 (en) | 2005-03-25 | 2007-12-19 | Glaxo Group Limited | Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives |
| FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| CN101243081A (zh) * | 2005-07-21 | 2008-08-13 | 霍夫曼-拉罗奇有限公司 | 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物 |
| AU2006279992A1 (en) | 2005-08-09 | 2007-02-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| FR2910813B1 (fr) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| BRPI0922154A2 (pt) * | 2008-12-01 | 2016-01-05 | Merck Patent Gmbh | pirido[4,3-d]pirimidinas 2,5-diamino-substituídas como inibidores de autotaxina contra o cãncer |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US9815847B2 (en) | 2013-03-14 | 2017-11-14 | Icahn School Of Medicine At Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR101671404B1 (ko) * | 2014-09-02 | 2016-11-02 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도 |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU711426B2 (en) * | 1994-11-14 | 1999-10-14 | Warner-Lambert Company | 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| BR9911590A (pt) * | 1998-05-26 | 2001-02-13 | Warner Lambert Co | Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular |
-
2001
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Ceased
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 PL PL01356802A patent/PL356802A1/xx not_active Application Discontinuation
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/en not_active Ceased
- 2001-01-23 CA CA002397961A patent/CA2397961C/en not_active Expired - Fee Related
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 EP EP01900591A patent/EP1254137A1/en not_active Withdrawn
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
-
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2002002586A0 (en) | Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. | |
| BG106594A (en) | Pteridinones as kinase inhibitors | |
| RU2441869C2 (ru) | Противовирусные соединения | |
| AP2000001964A0 (en) | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation. | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| BG107161A (en) | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors | |
| NZ627709A (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
| RU2005127052A (ru) | Соединения тиенопиримидина и их применение | |
| GEP20063915B (en) | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| HRP20120351T1 (hr) | Macrociklički derivati kinazolina kao antiproliferativna sredstva | |
| TW221434B (cs) | ||
| GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
| ZA200206191B (en) | Pyrimidine compounds. | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| EP1233950A4 (en) | 3,4-DIHYDRO (1H) CHINAZOLIN 2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS | |
| CA2997039A1 (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| DK0888356T3 (da) | Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere | |
| WO2002030932A3 (en) | N8,n13-disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | |
| TH53887A (th) | ไพริโด (2,3-d) , ไพริมิดีน-2.7- ไดเอมีนที่เป็นสารยับยั้งคิเนส | |
| PE20020513A1 (es) | COMPUESTOS DE 2,4,8-TRISUSTITUIDA-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA |